Treating depression with ketamine: We need incremental treatment for depression
Recently, the Food and Drug Administration approved a nasal spray version of the drug Ketamine, named Spravato (esketamine), for use as a supplement to oral antidepressants taken by adults living with treatment-resistant depression.
The announcement was accompanied by a flurry of media excitement as Spravato is the first medication for depression with a new mechanism of action since Prozac (fluoxetine hydrochloride) was approved in the late 1980s.
The risks …
Treating depression with ketamine: We need incremental treatment for depression






![Politics and fear have replaced science in U.S. pain management [PODCAST]](https://kevinmd.com/wp-content/uploads/11c2db8f-2b20-4a4d-81cc-083ae0f47d6e-190x100.jpeg)







![Why I would never compromise on withdrawing care until I saw it firsthand [PODCAST]](https://kevinmd.com/wp-content/uploads/Gemini_Generated_Image_6l3h566l3h566l3h-190x100.png)

